Randomized Parallel Controlled Study of Wenfeizhiluidan in the Treatment of Allergic Rhinitis with Deficiency of Lung Qi and Cold

Abstract

Objective — To study a randomized parallel control study of allergic rhinitis. Methods — 106 patients with lung qi deficiency and cold allergic rhinitis treated in the hospital from March 2022 to March 2023 were selected as the study objects. The patients were divided into observation group and control group according to the random parity method. 53 patients in each group took desloratadine, and the observation group took warm lung flow stop for treatment. The clinical effect, the level of inflammatory factors before and after treatment, and the immune function were compared between the two groups. Results — For the observed and control groups, 96.23% was higher than 75.47% (P<0.05). After treatment, the TNSS and RQLQ scores between the observation and control groups were lower (P<0.05). IL-33, TNF- α, and IFN- γ levels were lower in the observed and control groups (P<0.05). IgE, EOS and EOT were higher in observation and control groups (P<0.05). Conclusion — Patients with lung qi deficiency cold allergic rhinitis after taking warm lung flow Dan treatment, the clinical effect is remarkable, can effectively improve the clinical symptoms of patients, reduce their inflammatory response, improve the immune function of patients, with high clinical application value.